Hemolysis and free hemoglobin revisited: Exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins

Dominik J. Schaer, Paul W. Buehler, Abdu I. Alayash, John D. Belcher, Gregory M. Vercellotti

Research output: Contribution to journalReview article

286 Citations (Scopus)

Abstract

Hemolysis occurs in many hematologic and nonhematologic diseases. Extracellular hemoglobin (Hb) has been found to trigger specific pathophysiologies that are associated with adverse clinical outcomes in patients with hemolysis, such as acute and chronic vascular disease, inflammation, thrombosis, and renal impairment. Among the molecular characteristics of extracellular Hb, translocation of the molecule into the extravascular space, oxidative and nitric oxide reactions, hemin release, and molecular signaling effects of hemin appear to be the most critical. Limited clinical experience with a plasma-derived haptoglobin (Hp) product in Japan and more recent preclinical animal studies suggest that the natural Hb and the hemin-scavenger proteins Hp and hemopexin have a strong potential to neutralize the adverse physiologic effects of Hb and hemin. This includes conditions that are as diverse as RBC transfusion, sickle cell disease, sepsis, and extracorporeal circulation. This perspective reviews the principal mechanisms of Hb and hemin toxicity in different disease states, updates how the natural scavengers efficiently control these toxic moieties, and explores critical issues in the development of human plasma-derived Hp and hemopexin as therapeutics for patients with excessive intravascular hemolysis.

Original languageEnglish (US)
Pages (from-to)1276-1284
Number of pages9
JournalBlood
Volume121
Issue number8
DOIs
StatePublished - Feb 21 2013

Fingerprint

Hemin
Hemolysis
Hemoglobins
Haptoglobins
Hemopexin
Proteins
Plasma (human)
Therapeutics
Extracorporeal Circulation
Hematologic Diseases
Poisons
Sickle Cell Anemia
Human Development
Vascular Diseases
Toxicity
Sepsis
Japan
Nitric Oxide
Animals
Thrombosis

Cite this

Hemolysis and free hemoglobin revisited : Exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. / Schaer, Dominik J.; Buehler, Paul W.; Alayash, Abdu I.; Belcher, John D.; Vercellotti, Gregory M.

In: Blood, Vol. 121, No. 8, 21.02.2013, p. 1276-1284.

Research output: Contribution to journalReview article

@article{df2d1a3e9b844073a733d1a4835caf2c,
title = "Hemolysis and free hemoglobin revisited: Exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins",
abstract = "Hemolysis occurs in many hematologic and nonhematologic diseases. Extracellular hemoglobin (Hb) has been found to trigger specific pathophysiologies that are associated with adverse clinical outcomes in patients with hemolysis, such as acute and chronic vascular disease, inflammation, thrombosis, and renal impairment. Among the molecular characteristics of extracellular Hb, translocation of the molecule into the extravascular space, oxidative and nitric oxide reactions, hemin release, and molecular signaling effects of hemin appear to be the most critical. Limited clinical experience with a plasma-derived haptoglobin (Hp) product in Japan and more recent preclinical animal studies suggest that the natural Hb and the hemin-scavenger proteins Hp and hemopexin have a strong potential to neutralize the adverse physiologic effects of Hb and hemin. This includes conditions that are as diverse as RBC transfusion, sickle cell disease, sepsis, and extracorporeal circulation. This perspective reviews the principal mechanisms of Hb and hemin toxicity in different disease states, updates how the natural scavengers efficiently control these toxic moieties, and explores critical issues in the development of human plasma-derived Hp and hemopexin as therapeutics for patients with excessive intravascular hemolysis.",
author = "Schaer, {Dominik J.} and Buehler, {Paul W.} and Alayash, {Abdu I.} and Belcher, {John D.} and Vercellotti, {Gregory M.}",
year = "2013",
month = "2",
day = "21",
doi = "10.1182/blood-2012-11-451229",
language = "English (US)",
volume = "121",
pages = "1276--1284",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Hemolysis and free hemoglobin revisited

T2 - Exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins

AU - Schaer, Dominik J.

AU - Buehler, Paul W.

AU - Alayash, Abdu I.

AU - Belcher, John D.

AU - Vercellotti, Gregory M.

PY - 2013/2/21

Y1 - 2013/2/21

N2 - Hemolysis occurs in many hematologic and nonhematologic diseases. Extracellular hemoglobin (Hb) has been found to trigger specific pathophysiologies that are associated with adverse clinical outcomes in patients with hemolysis, such as acute and chronic vascular disease, inflammation, thrombosis, and renal impairment. Among the molecular characteristics of extracellular Hb, translocation of the molecule into the extravascular space, oxidative and nitric oxide reactions, hemin release, and molecular signaling effects of hemin appear to be the most critical. Limited clinical experience with a plasma-derived haptoglobin (Hp) product in Japan and more recent preclinical animal studies suggest that the natural Hb and the hemin-scavenger proteins Hp and hemopexin have a strong potential to neutralize the adverse physiologic effects of Hb and hemin. This includes conditions that are as diverse as RBC transfusion, sickle cell disease, sepsis, and extracorporeal circulation. This perspective reviews the principal mechanisms of Hb and hemin toxicity in different disease states, updates how the natural scavengers efficiently control these toxic moieties, and explores critical issues in the development of human plasma-derived Hp and hemopexin as therapeutics for patients with excessive intravascular hemolysis.

AB - Hemolysis occurs in many hematologic and nonhematologic diseases. Extracellular hemoglobin (Hb) has been found to trigger specific pathophysiologies that are associated with adverse clinical outcomes in patients with hemolysis, such as acute and chronic vascular disease, inflammation, thrombosis, and renal impairment. Among the molecular characteristics of extracellular Hb, translocation of the molecule into the extravascular space, oxidative and nitric oxide reactions, hemin release, and molecular signaling effects of hemin appear to be the most critical. Limited clinical experience with a plasma-derived haptoglobin (Hp) product in Japan and more recent preclinical animal studies suggest that the natural Hb and the hemin-scavenger proteins Hp and hemopexin have a strong potential to neutralize the adverse physiologic effects of Hb and hemin. This includes conditions that are as diverse as RBC transfusion, sickle cell disease, sepsis, and extracorporeal circulation. This perspective reviews the principal mechanisms of Hb and hemin toxicity in different disease states, updates how the natural scavengers efficiently control these toxic moieties, and explores critical issues in the development of human plasma-derived Hp and hemopexin as therapeutics for patients with excessive intravascular hemolysis.

UR - http://www.scopus.com/inward/record.url?scp=84874439878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874439878&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-11-451229

DO - 10.1182/blood-2012-11-451229

M3 - Review article

C2 - 23264591

AN - SCOPUS:84874439878

VL - 121

SP - 1276

EP - 1284

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -